Scholarlink

Background <p>There is an urgent need to evaluate the efficacy of novel therapeutics that have been approved for use in adults with IgA nephropathy (IgAN) in pediatric patients with this primary glomerular disease.</p> Methods <p>To explore the feasibility of deploying extrapolation to promote clinical trials in pediatric patients with IgA nephropathy (IgAN), an artificial intelligence (AI)–enhanced review of the published literature through 2023 was conducted to characterize the epidemiology and natural history of IgA nephropathy, summarize the clinical trial experience, and identify potential biomarkers for use in patient care and clinical trials.</p> Results <p>Using Distiller SR® software to identify relevant articles and Elicit®, an artificial intelligence tool to extract content, 83 articles were included in the review. The clinical trial reports (<i>n</i> = 9) and biomarker studies (<i>n</i> = 33) were limited in scope. The natural history and epidemiology articles (<i>n</i> = 41) suggested that the severity of kidney histopathology at the time of diagnosis indicated a higher risk of disease progression while proteinuria &lt; 0.5–1&#xa0;mg/mg creatinine was associated with a more favorable prognosis.</p> Conclusions <p>In conjunction with the similar biological basis of the disease in pediatric and adult patients, these findings may enable the use of extrapolation in the design of clinical trials in pediatric patients with IgAN.</p> Graphical Abstract <p>A higher resolution version of the Graphical abstract is available as <InternalRef RefID="MOESM1">Supplementary information</InternalRef></p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence–enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月8日

查看全文
  • David T. Selewski,
  • Eleanor M. Kerr,
  • Cecile Fajardo,
  • Barbara S. Gillespie,
  • Sai Prasad N. Iyer,
  • Myda Khalid,
  • Radko Komers,
  • Koichi Nakanishi,
  • Raoul D. Nelson,
  • Jun Oh,
  • Bonnie Schneider,
  • Lokesh N. Shah,
  • Nicholas J. Webb,
  • Xuhui Zhong,
  • Grace Squillaci,
  • Mark D. Lim,
  • Howard Trachtman

摘要

Background

There is an urgent need to evaluate the efficacy of novel therapeutics that have been approved for use in adults with IgA nephropathy (IgAN) in pediatric patients with this primary glomerular disease.

Methods

To explore the feasibility of deploying extrapolation to promote clinical trials in pediatric patients with IgA nephropathy (IgAN), an artificial intelligence (AI)–enhanced review of the published literature through 2023 was conducted to characterize the epidemiology and natural history of IgA nephropathy, summarize the clinical trial experience, and identify potential biomarkers for use in patient care and clinical trials.

Results

Using Distiller SR® software to identify relevant articles and Elicit®, an artificial intelligence tool to extract content, 83 articles were included in the review. The clinical trial reports (n = 9) and biomarker studies (n = 33) were limited in scope. The natural history and epidemiology articles (n = 41) suggested that the severity of kidney histopathology at the time of diagnosis indicated a higher risk of disease progression while proteinuria < 0.5–1 mg/mg creatinine was associated with a more favorable prognosis.

Conclusions

In conjunction with the similar biological basis of the disease in pediatric and adult patients, these findings may enable the use of extrapolation in the design of clinical trials in pediatric patients with IgAN.

Graphical Abstract

A higher resolution version of the Graphical abstract is available as Supplementary information